This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
MPT in Development
Preclinical – Early (Pre1)
Delivery Route & Method:
Mechanism of Action:
Recombinant non-ARV live biotherapeutic product, manufactured in tobacco plants.
University of Louisville
Nat. Institute Allergy & Infect. Diseases (NIAID)
Description: The antiviral lectin Griffithsin (GRFT) has broad-spectrum activity against human immunodeficiency viruses (HIV) types 1 and 2, herpes simplex virus type 2 (HSV-2) and hepatitis C virus (HCV). The product target is a rectal microbicide gel, containing GRFT as the primary Active Pharmaceutical Ingredient (API).
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.